Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma

Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma

Patients with advanced hepatocellular carcinoma (HCC) are not sensitive to sorafenib (SOR), therefore, combination therapy is required. In this study, an improved thin-film dispersion and post-insertion anchoring technique was utilized to construct a dual-targeted co-delivery SOR and docetaxel (DTX)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yawen Yao, Yue Hu, Xinwang Meng, Fenyan Feng, Feng Xu, Guangji Wang, Hua Yu, Juan Li
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Pharmaceutical Science Advances
Subjects:	Sorafenib Docetaxel Dual-targeting liposomes Combination therapy Advanced hepatocellular carcinoma
Online Access:	http://www.sciencedirect.com/science/article/pii/S2773216924000126
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
by: Angélica Richart Csipak, et al.
Published: (2024-11-01)

Enhancing in Vitro anti-metastatic efficacy and deep penetration into tumor spheroid of docetaxel-loaded liposomes via size optimization for prostate cancer treatment
by: Saksorn Klibaim, et al.
Published: (2025-03-01)

Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01)

Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
by: Wenjun Meng, et al.
Published: (2024-12-01)

Resveratrol liposomes reverse sorafenib resistance in renal cell carcinoma models by modulating PI3K-AKT-mTOR and VHL-HIF signaling pathways
by: Ligang Wang, et al.
Published: (2024-12-01)

ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma
by: Ying Shi, et al.
Published: (2023-02-01)

Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
by: Reham Ashour, et al.
Published: (2024-11-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE
by: Lu Xin, et al.
Published: (2024-11-01)

GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma
by: Shiwen Ma, et al.
Published: (2024-12-01)

Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
by: Yirui Zhai, et al.
Published: (2025-03-01)

Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01)

Adjuvant sorafenib for hepatocellular carcinoma after radiofrequency ablation versus radiofrequency ablation: analysis of its efficacy and safety
by: Wang Junxiao, et al.
Published: (2024-12-01)

Circ_0001944 Targets the miR-1292-5p/FBLN2 Axis to Facilitate Sorafenib Resistance in Hepatocellular Carcinoma by Impeding Ferroptosis
by: Jing F, et al.
Published: (2024-11-01)

Targeting AMP‐activated kinase impacts hepatocellular cancer stem cells induced by long‐term treatment with sorafenib
by: Alicia Bort, et al.
Published: (2019-05-01)

Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs
by: Lin Xu, et al.
Published: (2024-12-01)

HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib
by: Yingai Zhang, et al.
Published: (2025-01-01)

Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study
by: Li Sijin, et al.
Published: (2024-12-01)

Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma
by: Xiangbo Huang, et al.
Published: (2024-11-01)

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)

ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer
by: Yang-Hsiang Lin, et al.
Published: (2025-02-01)

CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis
by: Ying Zhang, et al.
Published: (2025-01-01)

Ferroptosis: insight into the treatment of hepatocellular carcinoma
by: Chuanjie Liao, et al.
Published: (2024-11-01)

Bufonis venenum extract loaded novel cholesterol-free liposome for the treatment of hepatocellular carcinoma
by: Siqi Yang, et al.
Published: (2024-11-01)

Effective Use of <i>Euphorbia milii</i> DCM Root Extract Encapsulated by Thermosensitive Immunoliposomes for Targeted Drug Delivery in Prostate Cancer Cells
by: Keamogetswe Riet, et al.
Published: (2024-10-01)

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
by: Pusen Wang, et al.
Published: (2020-10-01)

Feasibility and predictive factors on the completion of docetaxel plus S‐1 adjuvant chemotherapy in pathological stage III gastric cancer
by: Masayoshi Terayama, et al.
Published: (2025-01-01)

Liposomes and Their Therapeutic Applications in Enhancing Psoriasis and Breast Cancer Treatments
by: Amal Ali Elkordy, et al.
Published: (2024-11-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

(−)-Epigallocatechin-3-Gallate and Quercetin Inhibit Quiescin Sulfhydryl Oxidase 1 Secretion from Hepatocellular Carcinoma Cells
by: Lumin Yang, et al.
Published: (2025-01-01)

Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression
by: Steffen Markus Heckl, et al.
Published: (2025-01-01)

Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin
by: Hassan Bardania, et al.
Published: (2024-11-01)

Dual Roles of microRNA-122 in Hepatocellular Carcinoma and Breast Cancer Progression and Metastasis: A Comprehensive Review
by: Essam Al Ageeli
Published: (2024-10-01)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
by: Songporn Oranratnachai, et al.
Published: (2023-02-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Comparative study of liposomes and liposomes-in-polymer hydrogel as transdermal carriers for improving the topical delivery of imperatorin
by: Junfeng BAN, et al.
Published: (2021-03-01)

Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces
by: Hao Wang, et al.
Published: (2024-10-01)

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System
by: Dongdong Zhang, et al.
Published: (2024-12-01)

Targeted regulation of autophagy using sorafenib-loaded biomineralization nanoenzyme for enhanced photodynamic therapy of hepatoma
by: Tianming Lu, et al.
Published: (2024-12-01)

PTGES3 proteolysis using the liposomal peptide-PROTAC approach
by: Shiwei Liu, et al.
Published: (2024-12-01)